Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 5.66m |
Free float | 4.41m |
P/E (TTM) | -- |
Market cap | 43.72m USD |
EPS (TTM) | -39.90 USD |
--
More ▼
Press releases
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics Announces $36 Million Registered Direct Offering
- Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
- Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
- Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
More ▼